Clinical Trial

Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A

Name: Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A — clinical trial record (NCT06961500)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: PROOF

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multicenter, phase 2, randomized trial to evaluate the efficacy and safety of obinutuzumab with CHOP versus obinutuzumab with bendamustine in treatment-naïve follicular lymphoma (Grade 3A) patients.

Trial Details

NCT Number	NCT06961500
Lead Sponsor	Sun Yat-sen University
Conditions	Follicular Lymphoma Grade 3A
Enrollment	133 participants
Start Date	2025-05-01
Primary Completion	2030-11-01 (estimated)
Study Completion	2030-11-01 (estimated)
Updated on ClinicalTrials.gov	2025-05-08